Baseline characteristics at ABA initiation across nine European registries
| Registers | Follow-up (pt-years) | Folllow-up /pt | Male % | Age (years) | RF % | Anti-CCP % | Disease duration (years) | HAQ* | DAS28 | BMI (kg/m2) | CRP (mg/L) | ESR (mm/h) | sDMARDs (n) | bDMARDs (n) | Median year of ABA initiation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Combined(3961 pts) | 6188 | 1.1(0.5–2.4) | 19.4 | 57.3±13.0 | 76.8 | 68.3 | 11.3±8.1 | 1.3±0.7 | 5.0±1.3 | 26.0±5.1 | 22.2±34.2 | 31.6±24.4 | 2.4±1.8 2 (1–3) | 1.8±1.4 2 (1–3) | 2009 |
| ARTIS(1019 pts) | 1615 | 1.0(0.5–2.1) | 20.7 | 58.6±12.4 | _ | _ | 9.6±3.9 | 1.3±0.7 | 5.1±1.3 | 24.8±1.5 | 19.6±26.5 | 30.4±23.0 | 1.6±1.0 1 (1–2) | 1.9±1.3 2 (1–3) | 2011 |
| ATTRA(215 pts) | 356 | 1.2(0.6–2.6) | 20.9 | 50.1±12.5 | 70.1 | 74.7 | 11.2±7.7 | 1.5±0.5 | 5.7±1.1 | 25.5±4.9 | 25.7±29.3 | 38.3±24.3 | 3.7±1.7 4 (2–5) | __ | 2010 |
| BIOBADASER(283 pts) | 507 | 1.5(0.7–2.5) | 18.4 | 56.6±13.1 | 83.7 | 60 | 12.1±8.4 | 1.7±0.7 | 5.1±1.6 | _ | 18.1±26.0 | 33.6±27.7 | ± | 2.3±1.9 2 (1–3) | 2010 |
| DANBIO(315 pts) | 437 | 0.8(0.4–2.0) | 19.0 | 56.0±12.5 | 84.3 | 59.3 | 11.4±9.6 | 1.4±0.7 | 4.9±1.2 | 26.3±5.6 | 18.3±26.2 | _ | 4.3±2.2 4 (3–6) | 1.4±1.1 1 (1–2) | 2010 |
| GISEA(375 pts) | 503 | 1.1(0.5–2.0) | 13.3 | 56.5±12.5 | 73.6 | 81.7 | 10.6±8.4 | 1.4±0.8 | 5.0±1.1 | 25.8±5.0 | 39.0±66.0 | 34.4±23.4 | 2.5±1.5 2 (2–3) | 1.4±1.0 1 (1–2) | 2010 |
| NOR-DMARD(52 pts) | 54 | 0.7(0.4–1.1) | 11.5 | 51.3±12.5 | 59.6 | 48.9 | 14.8±9.7 | 0.9±0.5 | 5.4±1.1 | 24.0±4.1 | 24.2±34.2 | 36.4±28.1 | 3.2±1.5 3 (2–4) | 2.3±1.1 2 (2–3) | 2009 |
| ORA(1019 pts) | 1832 | 1.4(0.6–2.9) | 20.8 | 58.2±13.6 | 71.2 | 69.7 | 13.6±9.5 | 1.2±0.7 | 5.3±1.2 | _ | 25.1±32.8 | 35.5±27.7 | 3.1±1.8 3 (2–4) | 2.3±1.3 2 (1–3) | 2008 |
| REUMA.PT (37 pts) | 48 | 1.2(0.5–1.6) | 13.5 | 59.0±14.1 | 57.1 | 51.6 | 12.3±8.3 | 1.6±0.7 | 5.5±1.6 | 27.2±5.7 | 15.4±15.4 | 40.6±24.8 | 1.6±1.1 1 (1–3) | 2.0±1.3 2 (1–3) | 2010 |
| SCQM(646 pts) | 835 | 0.9(0.4–1.7) | 20.0 | 57.8±12.5 | 72.6 | 67.0 | 10.0±8.9 | 1.0±0.7 | 4.1±1.4 | 26.0±5.1 | 12.0±16.2 | 23.4±19.7 | 1.0±1.1 1 (0–2) | 1.2±1.2 1 (0–2) | 2010 |
*Values are means±SD and median [IQR], unless otherwise noted.
ABA, abatacept; BMI, body mass index; bDMARDs, biological disease modifying antirheumatic drugs; CCP, CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; pts, patients; RF, rheumatoid factor; sDMARDs, synthetic DMARDs.